8-K: Herbalife Reports Q1 2025 Results: Net Sales at Midpoint of Guidance, Adjusted EBITDA Exceeds Expectations, Full-Year Guidance Updated

Herbalife's Q1 2025 net sales reached $1.2 billion, hitting the midpoint of its guidance, while adjusted EBITDA exceeded expectations, leading to an updated full-year guidance.

Summary

• Herbalife reported net sales of $1.2 billion for Q1 2025, a 3.4% decrease compared to Q1 2024, but within the guidance range.
• Excluding foreign exchange headwinds, net sales increased by 1.4% year-over-year.
• Net income was $50.4 million, and adjusted net income was $59.9 million.
• Adjusted EBITDA exceeded guidance at $164.9 million, or $181.5 million on a constant currency basis.
• The adjusted EBITDA margin increased by 260 basis points compared to Q1 2024.
• Diluted EPS was $0.49, and adjusted diluted EPS was $0.59.
• The company completed acquisitions of certain assets of Pro2col Health LLC and Pruvit Ventures, Inc., and formed HBL Link Bioscience LLC.
• Full-year 2025 guidance was revised, with a narrowed net sales range and increased adjusted EBITDA.
• The total leverage ratio was reduced to 3.0x at the end of March.
• The company redeemed $65.0 million of its 7.875% Senior Notes due 2025 in February 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While net sales were down year-over-year, adjusted EBITDA exceeded guidance, and the company is making strategic acquisitions. The revised full-year guidance also indicates confidence in future performance.

Positives

• Net sales reached the midpoint of the guidance range.
• Adjusted EBITDA exceeded expectations.
• The total leverage ratio was reduced to 3.0x.
• New distributor numbers increased by 16% year-over-year.
• Gross profit margin improved to 78.3% compared to 77.5% in Q1 2024.
• The company is seeing positive momentum from new business initiatives and training events.
• Full-year adjusted EBITDA guidance was raised.

Negatives

• Net sales decreased by 3.4% compared to Q1 2024.
• Foreign exchange headwinds negatively impacted net sales by 480 basis points.
• China sales decreased by 13.8% year-over-year.

Risks

• Global economic conditions, including inflation and unfavorable foreign exchange rates, could impact the company's performance.
• The company's ability to attract and retain members is crucial for its success.
• Legal and regulatory matters, including challenges to the network marketing program, could pose risks.
• Disruptions to the business caused by natural disasters, acts of war, or cybersecurity incidents could negatively impact operations.
• The company's reliance on its information technology infrastructure presents a risk of security breaches or noncompliance with privacy laws.
• The company's ability to source ingredients and manufacture products is subject to potential disruptions.

Future Outlook

Herbalife has revised its full-year 2025 guidance, narrowing the net sales range and raising the adjusted EBITDA guidance. The company expects continued growth and positive momentum from its new business initiatives.

Management Comments

• '2025 is off to a strong start,' said John DeSimone, Chief Financial Officer.
• We delivered net sales growth on a constant currency basis1 for the second consecutive quarter, adjusted EBITDA2 exceeded guidance, and we reduced our total leverage ratio to 3.0x, a target achieved ahead of plan.
• 'As I transition into the role of CEO, I am committed to honoring Herbalifes 45-year legacy of empowering our communities through health, wellness and a strong entrepreneurial opportunity,' said Stephan Gratziani.
• Our recent acquisitions are a bold step to provide innovation and growth as we move toward our vision of becoming the worlds premier health and wellness company, community and platform.

Industry Context

Herbalife's focus on personalized nutrition and digital platforms aligns with the broader industry trend of leveraging technology to enhance customer engagement and product offerings. The acquisitions of Pro2col, Pruvit, and Link BioSciences reflect a strategic move to expand into personalized health and wellness solutions.

Comparison to Industry Standards

• Herbalife's adjusted EBITDA margin of 13.5% is comparable to other established direct selling companies like Nu Skin Enterprises (estimated 12-14% EBITDA margin) and USANA Health Sciences (estimated 11-13% EBITDA margin).
• The company's focus on distributor training and engagement programs mirrors similar initiatives by Amway and Tupperware, which also rely on a strong network of independent distributors.
• The acquisition of technology platforms like Pro2col is similar to moves by other health and wellness companies to integrate digital tools for personalized recommendations, such as Weight Watchers' emphasis on digital coaching and app-based support.

Management Changes

Stakeholder Impact

• Shareholders may see a positive impact from the increased adjusted EBITDA guidance and strategic acquisitions.
• Distributors will have access to new tools and resources through the Pro2col platform, potentially expanding their customer base.
• Customers may benefit from personalized nutrition recommendations and products through the acquired technologies.
• Employees may experience changes due to the integration of the acquired companies and new strategic initiatives.

Next Steps

• Launch a beta version of the Pro2col technology platform at the Herbalife North America Extravaganza at the end of July 2025.
• Commercial release of the Pro2col technology platform in the U.S. planned for the fourth quarter of 2025.
• Expansion of the Pro2col technology platform to additional markets beginning in 2026.
• Continued expansion of the Diamond Development Mastermind Program into additional markets.

Key Dates

Keywords

Herbalife, financial results, net sales, adjusted EBITDA, guidance, distributors, acquisitions, health and wellness, direct selling